Exploration of the Barriers to Clozapine Prescribing in Patients with Treatment-Resistant Schizophrenia: A Qualitative Study

J Psychosoc Rehabil Ment Health. 2023;10(1):45-53. doi: 10.1007/s40737-022-00287-3. Epub 2022 Aug 3.

Abstract

Treatment-resistance schizophrenia (TRS) is one of the psychiatric challenges. While clozapine is an effective treatment for patients with TRS, there are some barriers to clozapine prescribing in these patients. The study aims to explore the barriers from Iranian psychiatrists' points of view. The study was conducted by a qualitative approach using content analysis. The Participants included 12 psychiatrists who were selected purposefully. Data were collected using a semi-structured interview from May to December 2020. All interviews were recorded and transcribed and analyzed qualitatively using constant comparisons. Three main categories emerged concerning barriers to the use of clozapine: drug-related barriers, psychiatrist and health system-related barriers, and patient and family-related barriers. Additionally, specific subcategories within each main category were documented. The present study showed that there are three main groups of barriers to the use of clozapine in patients with TRS. Psychiatrist and health system-related barriers may influence the other two groups of barriers. Further research to investigate the effective strategies to overcome the barriers is recommended.

Keywords: Barriers; Clozapine; Qualitative study; Treatment-resistant schizophrenia.